Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry

The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.

In sufficiently high concentrations, elemental impurities, typically from catalyst residue, can pose safety risks. The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.

Articles in this issue

over 10 years ago

Article

Optimizing Tablet Compression

over 10 years ago

Article

Excipient Quality and Selection

over 10 years ago

Article

Filling the Analysis Gap in the Move to Continuous Processing

over 10 years ago

Article

Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

over 10 years ago

Article

Modeling and Simulation Move Downstream

over 10 years ago

Article

Unifying Excipient Databases

over 10 years ago

Article

Establishing a New Performance Standard for HPMC Capsules

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.